These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19347984)

  • 1. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
    Traynor AM; Dubey S; Eickhoff JC; Kolesar JM; Schell K; Huie MS; Groteluschen DL; Marcotte SM; Hallahan CM; Weeks HR; Wilding G; Espinoza-Delgado I; Schiller JH
    J Thorac Oncol; 2009 Apr; 4(4):522-6. PubMed ID: 19347984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
    Hoang T; Campbell TC; Zhang C; Kim K; Kolesar JM; Oettel KR; Blank JH; Robinson EG; Ahuja HG; Kirschling RJ; Johnson PH; Huie MS; Wims ME; Larson MM; Hernan HR; Traynor AM
    Invest New Drugs; 2014 Feb; 32(1):195-9. PubMed ID: 23728919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
    Crump M; Coiffier B; Jacobsen ED; Sun L; Ricker JL; Xie H; Frankel SR; Randolph SS; Cheson BD
    Ann Oncol; 2008 May; 19(5):964-9. PubMed ID: 18296419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.
    Schneider BJ; Kalemkerian GP; Bradley D; Smith DC; Egorin MJ; Daignault S; Dunn R; Hussain M
    Invest New Drugs; 2012 Feb; 30(1):249-57. PubMed ID: 20686817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    Kirschbaum M; Frankel P; Popplewell L; Zain J; Delioukina M; Pullarkat V; Matsuoka D; Pulone B; Rotter AJ; Espinoza-Delgado I; Nademanee A; Forman SJ; Gandara D; Newman E
    J Clin Oncol; 2011 Mar; 29(9):1198-203. PubMed ID: 21300924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
    Blumenschein GR; Kies MS; Papadimitrakopoulou VA; Lu C; Kumar AJ; Ricker JL; Chiao JH; Chen C; Frankel SR
    Invest New Drugs; 2008 Feb; 26(1):81-7. PubMed ID: 17960324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
    Woyach JA; Kloos RT; Ringel MD; Arbogast D; Collamore M; Zwiebel JA; Grever M; Villalona-Calero M; Shah MH
    J Clin Endocrinol Metab; 2009 Jan; 94(1):164-70. PubMed ID: 18854394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of vorinostat in advanced melanoma.
    Haas NB; Quirt I; Hotte S; McWhirter E; Polintan R; Litwin S; Adams PD; McBryan T; Wang L; Martin LP; vonMehren M; Alpaugh RK; Zweibel J; Oza A
    Invest New Drugs; 2014 Jun; 32(3):526-34. PubMed ID: 24464266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
    Vansteenkiste J; Van Cutsem E; Dumez H; Chen C; Ricker JL; Randolph SS; Schöffski P
    Invest New Drugs; 2008 Oct; 26(5):483-8. PubMed ID: 18425418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.
    Bradley D; Rathkopf D; Dunn R; Stadler WM; Liu G; Smith DC; Pili R; Zwiebel J; Scher H; Hussain M
    Cancer; 2009 Dec; 115(23):5541-9. PubMed ID: 19711464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
    Millward M; Price T; Townsend A; Sweeney C; Spencer A; Sukumaran S; Longenecker A; Lee L; Lay A; Sharma G; Gemmill RM; Drabkin HA; Lloyd GK; Neuteboom ST; McConkey DJ; Palladino MA; Spear MA
    Invest New Drugs; 2012 Dec; 30(6):2303-17. PubMed ID: 22080430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.
    Kirschbaum MH; Goldman BH; Zain JM; Cook JR; Rimsza LM; Forman SJ; Fisher RI
    Leuk Lymphoma; 2012 Feb; 53(2):259-62. PubMed ID: 21823829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
    Reguart N; Rosell R; Cardenal F; Cardona AF; Isla D; Palmero R; Moran T; Rolfo C; Pallarès MC; Insa A; Carcereny E; Majem M; De Castro J; Queralt C; Molina MA; Taron M
    Lung Cancer; 2014 May; 84(2):161-7. PubMed ID: 24636848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
    Duvic M; Talpur R; Ni X; Zhang C; Hazarika P; Kelly C; Chiao JH; Reilly JF; Ricker JL; Richon VM; Frankel SR
    Blood; 2007 Jan; 109(1):31-9. PubMed ID: 16960145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
    Galanis E; Jaeckle KA; Maurer MJ; Reid JM; Ames MM; Hardwick JS; Reilly JF; Loboda A; Nebozhyn M; Fantin VR; Richon VM; Scheithauer B; Giannini C; Flynn PJ; Moore DF; Zwiebel J; Buckner JC
    J Clin Oncol; 2009 Apr; 27(12):2052-8. PubMed ID: 19307505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
    Wada H; Tsuboi R; Kato Y; Sugaya M; Tobinai K; Hamada T; Shimamoto T; Noguchi K; Iwatsuki K
    J Dermatol; 2012 Oct; 39(10):823-8. PubMed ID: 22506596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
    Garcia-Manero G; Yang H; Bueso-Ramos C; Ferrajoli A; Cortes J; Wierda WG; Faderl S; Koller C; Morris G; Rosner G; Loboda A; Fantin VR; Randolph SS; Hardwick JS; Reilly JF; Chen C; Ricker JL; Secrist JP; Richon VM; Frankel SR; Kantarjian HM
    Blood; 2008 Feb; 111(3):1060-6. PubMed ID: 17962510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Modesitt SC; Sill M; Hoffman JS; Bender DP;
    Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
    Tambo Y; Hosomi Y; Sakai H; Nogami N; Atagi S; Sasaki Y; Kato T; Takahashi T; Seto T; Maemondo M; Nokihara H; Koyama R; Nakagawa K; Kawaguchi T; Okamura Y; Nakamura O; Nishio M; Tamura T
    Invest New Drugs; 2017 Apr; 35(2):217-226. PubMed ID: 28138828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
    Dasari A; Gore L; Messersmith WA; Diab S; Jimeno A; Weekes CD; Lewis KD; Drabkin HA; Flaig TW; Camidge DR
    Invest New Drugs; 2013 Feb; 31(1):115-25. PubMed ID: 22415798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.